Recommendation of the President – Pluvicto (lutetium (177Lu) vipivotide tetraxetan)
On 6 August 2025, the President of the Agency for Health Technology Assessment and Tariff System issued recommendation No. 110/2025 on the inclusion of the medicinal product Pluvicto (lutetium (177Lu) vipivotide tetraxetan) in the B.56 drug program “Treatment of patients with prostate cancer (ICD-10: C61)”